This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement N° 737817

The first enrollment in the ASTRAL-4LV clinical trial – 3 December 2020 

The first implantation of Axone as part of the ASTRAL-4LV study was successfully performed on December 3, 2020, by Professor Frédéric Anselme at the Rouen University Hospital in France. The purpose of the ASTRAL-4LV study is to assess the chronic safety and performance of the Axone lead for cardiac resynchronization therapy (CRT). “Approximately 30% of […]

European Heart Rhythm Association (EHRA) Congress 17-19 March 2019

INNOVATION LAB An innovation lab was present at MicroPort CRM’s booth, dedicated to the presentation of the Axone project and a demonstration of the product. In addition, an implant simulator was made available to physicians, to provide them with a hands-on handling experience on the Axone system. During the congress, a total of 135 physicians visited the […]